Category Archives: Uncategorized

Ceritinib and mutations

Abstract 9064 covers 85 patients but only 8 patients has ALK mutations and baseline biopsies collected within 14 days of progression . L1196M was most common. The study indicated that Ceritinib was potent against several known ALK mutations.

Posted in Uncategorized | Leave a comment

Info on Liquid biopsy

Abstract e20643 is only available online. In this trial, 10,000 solid cancer patients blood were tested by Guardian360 (a method that sequences compete exons (the part of the DNA that encodes for proteins)). Of those patients ALK fusions were detected … Continue reading

Posted in Lung cancer, Research, Uncategorized | Leave a comment

Tesaro update

As of November 29, 2014, Tesaro had published a poster for ECCO 2014. 40 patients in trial. 20 with NSCLC. 13 ALK +. 9 previously treated with Crizotinib. 4 partial responses. http://www.tesarobio.com/documents/TSR_011_EORTC_2014.pdf

Posted in Uncategorized | Leave a comment

Another imunotherapy update

On January 11th, Bristol-Myers announced the early termination of its trial of imunotherapy Opdivo (Nivolumab) for lung cancer due to positive results (a survival benefit that was so clear it was unethical to continue the trial for the control group). … Continue reading

Posted in Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Uncategorized | Leave a comment

MPDL3280A Breakthrough therapy for ALK resistance

Anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA as a potential treatment for patients with PD-L1–positive non–small cell lung cancer (NSCLC) who have progressed on platinum-based chemotherapy and a EGFR or ALK inhibitor. MPDL3280A is developed … Continue reading

Posted in Uncategorized | Leave a comment

Update on HMS and MGH Science article

They used a combination of a ALK inhibitor and a SRC inhibitor on 9 cell lines that had acquired ALK inhibitor resistance and on 2/3s there were significant results. In particular, they found that an SRC inhibitor, AZD0530 (saracatinib), when … Continue reading

Posted in Uncategorized | Leave a comment

Potentially overcoming Crizotinib resistance in ROS1

Cabozantinib appears to overcome crizotinib resistance in ROS1 fusion positive cancer. http://www.ncbi.nlm.nih.gov/pubmed/25351743

Posted in Uncategorized | Leave a comment

List of Videos from GRACE Acquired Resistance Patient Forum

Grace hosted an Acquired Resistance Patient Forum in Boston in September 2014. They covered acquired resistance for EGFR, ALK, AND ROS. They discussed potential causes of resistance and potential treatments. There was also a presentation on the FDA’s evolving perspective … Continue reading

Posted in Uncategorized | Leave a comment

ALK inhibitor + HSP90 inhibitor

From the NEJM A case study of combining AT13387 with crizotinib. http://www.nejm.org/doi/full/10.1056/NEJMc1410799

Posted in Uncategorized | Leave a comment

Video by Dr. Gandhi re: new ALK inhibitors

http://cancergrace.org/lung/2014/05/30/iaslc_gandhi_compare_new_old_alk_drugs/

Posted in Uncategorized | Leave a comment